₩1,691,000.00
69.10% yesterday
Korea, Dec 24, 07:30 am CET
ISIN
KR7207940008
Symbol
207940
Index

SAMSUNG BIOLOGICS Stock price

₩1,000,000.00
+0.00 0.00% 1M
+0.00 0.00% 6M
+0.00 0.00% YTD
+0.00 0.00% 1Y
+0.00 0.00% 3Y
+0.00 0.00% 5Y
+857,512.58 601.82% 10Y
+857,512.58 601.82% 20Y
Korea, Closing price Wed, Dec 24 2025
+0.00 0.00%
ISIN
KR7207940008
Symbol
207940
Index

Key metrics

Basic
Market capitalization
₩79.6t
Enterprise Value
₩78.9t
Net debt
positive
Cash
₩1.9t
Shares outstanding
71.2m
Valuation (TTM | estimate)
P/E
44.6 | 27.4
P/S
14.5 | 14.0
EV/Sales
14.3 | 13.9
EV/FCF
109.2
P/B
6.5
Financial Health
Equity Ratio
62.9%
Return on Equity
9.9%
ROCE
13.9%
ROIC
11.5%
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
₩5.5t | ₩5.7t
EBITDA
₩2.1t | ₩2.7t
EBIT
₩2.0t | ₩2.2t
Net Income
₩1.6t | ₩2.6t
Free Cash Flow
₩722.4b
Growth (TTM | estimate)
Revenue
26.1% | 24.7%
EBITDA
48.7% | 99.8%
EBIT
50.0% | 64.1%
Net Income
51.6% | 140.0%
Free Cash Flow
-27.7%
Margin (TTM | estimate)
Gross
56.3%
EBITDA
37.5% | 48.2%
EBIT
36.6%
Net
29.0% | 45.9%
Free Cash Flow
13.1%
More
EPS
₩22,422.4
FCF per Share
₩10,150.6
Short interest
-
Employees
-
Rev per Employee
-
Show more

Is SAMSUNG BIOLOGICS a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

SAMSUNG BIOLOGICS Stock Analysis

Unlock Scores for Free

Analyst Opinions

31 Analysts have issued a SAMSUNG BIOLOGICS forecast:

30x Buy
97%
1x Hold
3%

Analyst Opinions

31 Analysts have issued a SAMSUNG BIOLOGICS forecast:

Buy
97%
Hold
3%

Financial data from SAMSUNG BIOLOGICS

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
5,504,838 5,504,838
26% 26%
100%
- Direct Costs 2,405,427 2,405,427
9% 9%
44%
3,099,412 3,099,412
44% 44%
56%
- Selling and Administrative Expenses 861,221 861,221
30% 30%
16%
- Research and Development Expense 173,756 173,756
68% 68%
3%
2,064,435 2,064,435
49% 49%
38%
- Depreciation and Amortization 47,634 47,634
7% 7%
1%
EBIT (Operating Income) EBIT 2,016,800 2,016,800
50% 50%
37%
Net Profit 1,595,893 1,595,893
52% 52%
29%

In millions KRW.

Don't miss a Thing! We will send you all news about SAMSUNG BIOLOGICS directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

SAMSUNG BIOLOGICS Co., Ltd. engages in the provision of contract manufacturing organization services for pharmaceutical products. The company was founded on April 22, 2011 and is headquartered in Incheon, South Korea.

Head office South Korea
CEO John Rim
Founded 2011
Website samsungbiologics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today